UNITED STATES SECURITIES AND EXCHANGE

~~SECURITIES AND EXCHANGE~~ COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

For the month of ~~May~~ June 2026

Commission File Number: 001-36187

EVOGENE LTD.

(Translation of Registrant’s Name into English)

13 Gad Feinstein Street~~, Park Rehovot, Rehovot 7638517, Israel~~

Park Rehovot, Rehovot 7638517, Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

CONTENTS

OnAt ~~May~~The ~~20,~~Market 2026, Evogene Ltd. (“Evogene”) announced its financial results for the first quarter ended March 31, 2026. A Copy of the press release announcing those results is furnished as Exhibit 99.1 to this Report of Foreign Private Issuer on Form 6-K (this “Form 6-K”) and is incorporated herein by reference.Offering

On June 11, 2026, Evogene isLtd. ~~holding~~(the “Company”) entered into a ~~conference call~~Sales onAgreement ~~May~~(the 20“Sales Agreement”) with A.G.P./Alliance Global Partners (the “Agent”), ~~2026~~pursuant to ~~discuss~~which ~~its~~the ~~quarterly~~Company ~~results~~may ~~for~~offer ~~the~~and ~~quarter~~sell, ~~ended~~from ~~March~~time 31to time, ~~2026~~its ~~and~~ordinary shares, inpar ~~connection~~value ~~with~~NIS ~~that~~0.2 ~~call~~per share (“ordinary shares”), ~~will~~through ~~make available~~the toAgent ~~its~~in ~~investors~~an a“at ~~slide~~the ~~presentation~~market tooffering” ~~provide~~(the ~~additional~~“ATM ~~information~~Offering”), ~~regarding~~as ~~its~~defined ~~business~~in ~~and~~Rule ~~its~~415(a)(4) ~~financial~~promulgated ~~results.~~under ~~That slide~~the ~~presentation~~Securities isAct ~~attached~~of 1933, as ~~Exhibit~~amended ~~99.2~~(the to“Securities ~~this~~Act”), for ~~Form~~an ~~6-K~~aggregate ~~and~~offering isprice ~~incorporated~~of ~~herein~~up byto ~~reference~~$2,926,500.

~~The~~Any ~~GAAP~~ordinary ~~financial~~shares ~~statements tables~~offered ~~contained~~ in the ~~press~~ATM ~~release~~Offering ~~attached~~will tobe ~~this~~issued ~~Form~~pursuant ~~6-K~~to ~~are~~a ~~incorporated~~shelf ~~by reference in the~~ registration ~~statements~~statement on Form F-3 (File No. 333-277565) and the prospectus contained therein, which was declared effective by the Securities and Exchange Commission (the “SEC”) ~~File~~on NoMarch 28, 2024. ~~333-277565~~The Agent may sell ordinary shares (A), ~~and~~in ~~Form~~privately ~~S-8~~negotiated transactions with the Company’s consent or (~~SEC~~B) ~~File~~by ~~Nos.~~any ~~333-193788~~other method permitted by law deemed to be an ATM Offering, ~~333-201443~~including block transactions, sales made directly on the Nasdaq Stock Market or sales made into any other existing trading market for the Company’s ordinary shares. Subject to the terms and ~~333-203856~~ conditions of the Sales Agreement, ~~333-259215~~the Agent will use its commercially reasonable efforts to sell the Company’s ordinary shares from time to time, ~~and~~based ~~333-286197)~~upon ofits ~~Evogene~~instructions (including any price, ~~and~~time or size limits or other parameters or conditions that the Company may impose). The Company will bepay to the Agent a ~~part~~cash ~~thereof~~commission of 3.0% of the gross proceeds from the ~~date~~sale onof ~~which~~any ~~this~~ordinary ~~Form~~shares ~~6-K~~by isthe ~~submitted,~~Agent tounder the ~~extent~~ ~~not~~Sales ~~superseded~~Agreement. byThe ~~documents~~Company orand ~~reports~~the ~~subsequently~~Agent ~~filed~~have oralso ~~furnished~~provided each other with customary indemnification rights.

The Company is not obligated to make any sales of ordinary shares under the Sales Agreement and no assurance can be given that it will sell any ordinary shares under the Sales Agreement, or, if it does, as to the price or number of such shares that it will sell, or the dates on which any such sales will take place. The Sales Agreement may be terminated by either party as set forth in the Sales Agreement.

This Report of Foreign Private Issuer on Form 6-K (this “Report”) shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

The legal opinion of Meitar | Law Offices relating to the legality of the issuance and sale of the ordinary shares under the Sales Agreement is attached as Exhibit 5.1 to this Report.

The foregoing summary of the Sales Agreement does not purport to be complete and is qualified in its entirety by reference to the Sales Agreement, which is attached as Exhibit 10.1 to this Report and incorporated herein by reference.

The contents of this Report are incorporated by reference into the Company’s registration statements on Form F-3 (File Nos. 333-277565 and 333-294650) and Form S-8 (File Nos. 333-193788, 333-201443, 333-203856, 333-259215, 333-286197 and 333-294648), filed with the SEC, to be a part thereof from the date on which this Report is furnished, to the extent not superseded by documents or reports subsequently filed or furnished.

Exhibits

Exhibit No.	Description
5.1	Opinion of Meitar \| Law Offices.
10.1	Sales Agreement by and between Evogene Ltd. and A.G.P./Alliance Global Partners, dated June 11, 2026.
23.1	Consent of Meitar \| Law Offices (included in Exhibit 5.1).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: May 20, 2026 EVOGENE LTD. (Registrant) By: /s/ Ofer Haviv Ofer Haviv Chief Executive Officer

	EVOGENE LTD. (Registrant)

Date: June 11, 2026	By:	/s/ Ofer Haviv
		Ofer Haviv
		Chief Executive Officer

EXHIBIT INDEX

EXHIBIT NO.	DESCRIPTION
99.1	Press Release: Evogene Reports First Quarter 2026 Financial Results.
99.2	Slide presentation for conference call of Evogene held on May 20, 2026, discussing Evogene’s quarterly financial results for the first quarter of 2026.

Filing Compare · Evogene Ltd.